Time-to-Detection in Culture of Mycobacterium Tuberculosis
October 4, 2022 updated by: Centre Hospitalier Universitaire de Nice
Time-to-Detection in Culture of Mycobacterium Tuberculosis : Performance for Assessing Index Cases Infectivity
determination if time-to-detection in cultures of M. tuberculosis samples is more discriminating than acid-fast staining in transmission
Study Overview
Study Type
Observational
Enrollment (Actual)
705
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nice, France, 06000
- Nice University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 94 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
all cases of pulmonary tuberculosis who had a sample analysed by the laboratory of bacteriology of Nice University Hospital, and that was positive in culture before treatment and of which contact cases were explored by the CLAT
Description
Inclusion Criteria:
- have at least 1 contact case explored for tuberculosis
- latent tuberculosis infection
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Index cases
|
no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tuberculosis transmission
Time Frame: 2 months
|
duration of Tuberculosis transmission between an infected person and a contact case
|
2 months
|
|
contact case tracking
Time Frame: 2 months
|
screening time for contact cases
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2022
Primary Completion (Actual)
September 15, 2022
Study Completion (Actual)
September 15, 2022
Study Registration Dates
First Submitted
October 4, 2022
First Submitted That Met QC Criteria
October 4, 2022
First Posted (Actual)
October 5, 2022
Study Record Updates
Last Update Posted (Actual)
October 5, 2022
Last Update Submitted That Met QC Criteria
October 4, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22Infectio01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.